Drugs / 111In-DTPA-exendin-4
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT04733508 | Nov 2019 → Jun 2022 | type 2 diabetes mellitus | Radboud University Medical Center | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 111In-DTPA-exendin-4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04733508 ↗ |
| Modality | Diagnostic / imaging agent | “Radiolabelled exendin is therefore a valuable imaging agent for human beta cell mass quantification” PMID 39405026 ↗ Oct 2024 |
| Route | Other | “Injection of 111In-DTPA-exendin-4” NCT04733508 ↗ |